Source: Eur Respir Rev 2009; 18: 154-161
Disease area: Pulmonary vascular diseases

Abstract

Pulmonary arterial hypertension (PAH) commonly arises in patients with congenital heart disease (CHD). Greater numbers of patients with PAH associated with CHD (PAH-CHD) are now surviving into adulthood, many with increasingly complex cardiac defects. Patients with cardiac defects which result in left-to-right shunting are at risk of developing PAH, owing to the increased shear stress and circumferential stretch induced by increased pulmonary blood flow, which leads to endothelial dysfunction and progressive vascular remodelling and, thus, increased pulmonary vascular resistance. Although PAH-CHD shares similar lung histology with idiopathic PAH, differences do exist between these aetiologies. Management of PAH-CHD can involve surgical correction of the cardiac defect and/or treatment of the PAH, depending on the underlying cardiac defect and status of disease progression. Transplantation surgery can be curative but is not without limitations. The timing of intervention in patients with PAH-CHD is important, but the optimums are sometimes difficult to define, with limited robust data to inform management decisions. Uncontrolled studies suggest that prostacyclin analogues and phosphodiesterase type-5 inhibitors may have benefits in advanced pulmonary vascular disease. In the only randomised controlled trial dedicated to end-stage PAH-CHD, bosentan significantly reduced pulmonary vascular resistance and significantly increased 6-minute walk distance without compromising peripheral oxygen saturation, in patients with Eisenmenger syndrome. These data suggest that targeted therapies are beneficial in the PAH-CHD population, and warrant further research.

Rating:

Share or cite this content

Citations should be made in the following way:
Gatzoulis M. A., Alonso-Gonzalez R., Beghetti M.. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur Respir Rev 2009; 18: 154-161

Member's Comments

No comment yet.

Related content which might interest you: Changing demographics of pulmonary arterial hypertension in congenital heart disease Source: Eur Respir Rev 2010 19: 308-313 Year: 2010 Pulmonary arterial hypertension: a comparison between children and adults Source: Eur Respir J 2011; 37: 665-677 Year: 2011 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 Pulmonary arterial hypertension in children Source: Eur Respir J 2003; 21: 155-176 Year: 2003 Characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease in the French PAH registry Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Hemodynamic assessment of pulmonary hypertension in grown-up congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: end-points and biomarkers Year: 2012 Pulmonary hypertension in left heart, respiratory and trombo-embolic pulmonary disease Source: International Congress 2015 – Pulmonary hypertension Year: 2015 Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Pulmonary hypertension due to left heart disease Source: Eur Respir J, 53 (1) 1801897; 10.1183/13993003.01897-2018 Year: 2019 Pulmonary arterial hypertension associated with congenital heart disease Source: Eur Respir Rev 2012 21: 328-337 Year: 2012 Hemodynamic assessment of pulmonary hypertension in corrected versus non-corrected grown-up congenital heart disease Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Nebulised Iloprost for pulmonary arterial hypertension associated with congenital heart disease: one centre's experience Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Adult congenital heart disease and pulmonary hypertension: management of a complex case Source: Eur Respir Rev 2012 21: 362-364 Year: 2012 Pulmonary hypertension associated with congenital heart disease (PH-CHD): Results from the ASPIRE registry Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Managing pulmonary hypertension in patients with congenital heart disease Source: Eur Respir Mon 2012; 57: 71-81 Year: 2012 Pulmonary arterial hypertension related with congenital heart disease (PAH r-CHD): a retrospective study of 21 patients Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Pulmonary vascular distensibility in pulmonary hypertension due to left heart disease Source: International Congress 2018 – Pulmonary hypertension: right ventricle function, haemodynamics and exercise Year: 2018